Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis.

Makoto ChumaHaruki UojimaNobuhiro HattoriYoshitaka AraseTaito FukushimaShunji HiroseSatoshi KobayashiMakoto UenoShun TezukaShuichiro IwasakiNaohisa WadaKousuke KubotaKota TsuruyaYoshimasa ShimmaIkeda HirokiEhira TakuyaChikako TokoroShigeru IwaseYuki MiuraSatoshi MoriyaTsunamasa WatanabeHisashi HidakaManabu MorimotoKazushi NumataChika KusanoTatehiro KagawaShin Maeda

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2021)

In real-world practice, ATZ + BV treatment might offer significant benefits in patients who meet B-IMbrave150 criteria or have low NLR.

Keyphrases

clinical practice
primary care
healthcare
lipopolysaccharide induced
squamous cell carcinoma
cross sectional
clinical trial
quality improvement
rectal cancer